
ResMed Inc.: shareholders and insiders
Price
$235.63
November 20, 2026Market cap $34.0B
What Ploutos Investor adds for ResMed
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from FY2010
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 21, 2025 to Nov 20, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$20M
5 people
From Nov 21, 2025 to Nov 21, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan100%
- The rest0%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 21, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $18M by 5 people
- 2025: no buys, sold $2.5M by 5 people
- 2026: no buys, sold $18M by 5 people
- Nov 19, 2026Michael J. FarrellChairman and CEOKind
- Nov 19, 2026Michael J. FarrellChairman and CEOKind
- Nov 19, 2026Christopher DelOreficeDirectorKind
- Nov 19, 2026Michael J RiderGlobal General CounselKind
- Nov 19, 2026Michael J RiderGlobal General CounselKind
- Nov 19, 2026Harjit GillDirectorKind
- Nov 19, 2026Desney TanDirectorKind
- Nov 19, 2026John HernandezDirectorKind
- Nov 19, 2026Karen DrexlerDirectorKind
- Nov 19, 2026Justin LeongChief Product OfficerKind
- Nov 19, 2026Carol BurtDirectorKind
- Nov 19, 2026Peter C FarrellDirectorKind
- Nov 19, 2026Witte Jan DeDirectorKind
- Nov 17, 2026Witte Jan DeDirectorKind10b5-1
- Nov 11, 2026Michael J. FarrellChairman and CEOKind
- Nov 11, 2026Michael J. FarrellChairman and CEOKind
- Nov 11, 2026Michael J. FarrellChairman and CEOKind
- Nov 11, 2026Aaron BloomerChief Financial OfficerKind
- Nov 11, 2026Peter C FarrellDirectorKind
- Nov 11, 2026Witte Jan DeDirectorKind
- Nov 11, 2026Harjit GillDirectorKind
- Nov 11, 2026Michael J RiderGlobal General CounselKind
- Nov 11, 2026Michael J RiderGlobal General CounselKind
- Nov 11, 2026Michael J RiderGlobal General CounselKind
- Nov 11, 2026Michael J RiderGlobal General CounselKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 19, 2026 | Michael J. FarrellChairman and CEO | 48.1K | – | – | Form 4 | |
| Nov 19, 2026 | Michael J. FarrellChairman and CEO | 28.2K | $236.88 | $6.7M | Form 4 | |
| Nov 19, 2026 | Christopher DelOreficeDirector | 554 | – | – | Form 4 | |
| Nov 19, 2026 | Michael J RiderGlobal General Counsel | 5,587 | – | – | Form 4 | |
| Nov 19, 2026 | Michael J RiderGlobal General Counsel | 3,084 | $236.88 | $730.5K | Form 4 | |
| Nov 19, 2026 | Harjit GillDirector | 1,109 | – | – | Form 4 | |
| Nov 19, 2026 | Desney TanDirector | 1,109 | – | – | Form 4 | |
| Nov 19, 2026 | John HernandezDirector | 1,109 | – | – | Form 4 | |
| Nov 19, 2026 | Karen DrexlerDirector | 1,109 | – | – | Form 4 | |
| Nov 19, 2026 | Justin LeongChief Product Officer | 10.3K | – | – | Form 4 | |
| Nov 19, 2026 | Carol BurtDirector | 1,109 | – | – | Form 4 | |
| Nov 19, 2026 | Peter C FarrellDirector | 554 | – | – | Form 4 | |
| Nov 19, 2026 | Witte Jan DeDirector | 1,109 | – | – | Form 4 | |
| Nov 17, 2026 | Witte Jan DeDirector | 10b5-1 | 429 | $237.00 | $101.7K | Form 4 |
| Nov 11, 2026 | Michael J. FarrellChairman and CEO | 3,466 | $234.11 | $811.4K | Form 4 | |
| Nov 11, 2026 | Michael J. FarrellChairman and CEO | 2,210 | $234.11 | $517.3K | Form 4 | |
| Nov 11, 2026 | Michael J. FarrellChairman and CEO | 2,436 | $234.11 | $570.3K | Form 4 | |
| Nov 11, 2026 | Aaron BloomerChief Financial Officer | 1,095 | $234.11 | $256.4K | Form 4 | |
| Nov 11, 2026 | Peter C FarrellDirector | 169 | $234.11 | $39.6K | Form 4 | |
| Nov 11, 2026 | Witte Jan DeDirector | 60 | $234.11 | $14.0K | Form 4 | |
| Nov 11, 2026 | Harjit GillDirector | 36 | $234.11 | $8.4K | Form 4 | |
| Nov 11, 2026 | Michael J RiderGlobal General Counsel | 547 | $234.11 | $128.2K | Form 4 | |
| Nov 11, 2026 | Michael J RiderGlobal General Counsel | 499 | $234.11 | $116.7K | Form 4 | |
| Nov 11, 2026 | Michael J RiderGlobal General Counsel | 724 | $234.11 | $169.6K | Form 4 | |
| Nov 11, 2026 | Michael J RiderGlobal General Counsel | 173 | $234.11 | $40.5K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 3, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by RMD's officers and directors from 2006 up to November 20, 2025, 20 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 15 more, back to 2006
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Vanguard Capital ManagementShare of class8.21%
- AustralianSuper Pty LtdShare of class5.70%
- Vanguard Portfolio ManagementShare of class5.41%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Vanguard Capital Management | 8.21% | 11.96M | Apr 29, 2026 | 13G | |
| AustralianSuper Pty Ltd | 5.70% | 8.28M | Aug 7, 2026 | 13G | |
| Vanguard Portfolio Management | 5.41% | 7.89M | Apr 29, 2026 | 13G |
Fell to 5% or less (1)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
- The Vanguard Group0.00%Mar 27, 202613G/A
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Citadel Advisors (Griffin)In the quarter+3.9%
- AQR CapitalIn the quarter+3.7%
- Renaissance TechnologiesIn the quarter×58.0
- Millennium Mgmt (Englander)In the quarter-51%
- Bridgewater (Dalio)In the quarter-78%
- D.E. ShawIn the quarter-4.9%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Citadel Advisors (Griffin) | 527.9K | +3.9% | $117M | 0.06% |
| AQR Capital | 944.6K | +3.7% | $209M | 0.06% |
| Renaissance Technologies | 93.9K | ×58.0 | $21M | 0.03% |
| Millennium Mgmt (Englander) | 100.0K | -51% | $22M | 0.02% |
| Bridgewater (Dalio) | 14.5K | -78% | $3.2M | 0.01% |
| D.E. Shaw | 5,819 | -4.9% | $1.3M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 8.26% of its shares outstanding were held short, -6.7% since the report before.
- Shares held short
- 11.92M
- 8.26%
- Since the report before12.78M on Sep 30, 2026
- -6.7%
- 12.3
- 966.5K
- More days to cover thanof 4,578 US-listed companies with enough volume
- 96%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 5.72M
- Nov 15, 2023: Shares held short 6.31M
- Nov 30, 2023: Shares held short 5.85M
- Dec 15, 2023: Shares held short 5.81M
- Dec 29, 2023: Shares held short 5.67M
- Jan 12, 2024: Shares held short 5.89M
- Jan 31, 2024: Shares held short 6.33M
- Feb 15, 2024: Shares held short 6.58M
- Feb 29, 2024: Shares held short 6.76M
- Mar 15, 2024: Shares held short 7.66M
- Mar 28, 2024: Shares held short 7.89M
- Apr 15, 2024: Shares held short 7.95M
- Apr 30, 2024: Shares held short 9.85M
- May 15, 2024: Shares held short 10.21M
- May 31, 2024: Shares held short 9.87M
- Jun 14, 2024: Shares held short 8.24M
- Jun 28, 2024: Shares held short 8.58M
- Jul 15, 2024: Shares held short 8.48M
- Jul 31, 2024: Shares held short 8.90M
- Aug 15, 2024: Shares held short 9.78M
- Aug 30, 2024: Shares held short 8.55M
- Sep 13, 2024: Shares held short 8.58M
- Sep 30, 2024: Shares held short 8.57M
- Oct 15, 2024: Shares held short 8.66M
- Oct 31, 2024: Shares held short 7.89M
- Nov 15, 2024: Shares held short 7.31M
- Nov 29, 2024: Shares held short 7.54M
- Dec 13, 2024: Shares held short 7.81M
- Dec 31, 2024: Shares held short 7.91M
- Jan 15, 2025: Shares held short 8.04M
- Jan 31, 2025: Shares held short 8.30M
- Feb 14, 2025: Shares held short 9.71M
- Feb 28, 2025: Shares held short 8.73M
- Mar 14, 2025: Shares held short 8.73M
- Mar 31, 2025: Shares held short 8.90M
- Apr 15, 2025: Shares held short 9.11M
- Apr 30, 2025: Shares held short 9.43M
- May 15, 2025: Shares held short 10.93M
- May 30, 2025: Shares held short 10.59M
- Jun 13, 2025: Shares held short 9.93M
- Jun 30, 2025: Shares held short 10.13M
- Jul 15, 2025: Shares held short 9.38M
- Jul 31, 2025: Shares held short 9.02M
- Aug 15, 2025: Shares held short 8.94M
- Aug 29, 2025: Shares held short 8.51M
- Sep 15, 2025: Shares held short 8.65M
- Sep 30, 2025: Shares held short 8.81M
- Oct 15, 2025: Shares held short 8.96M
- Oct 31, 2025: Shares held short 9.69M
- Nov 14, 2025: Shares held short 10.65M
- Nov 28, 2025: Shares held short 10.42M
- Dec 15, 2025: Shares held short 10.56M
- Dec 31, 2025: Shares held short 11.67M
- Jan 15, 2026: Shares held short 11.43M
- Jan 30, 2026: Shares held short 11.12M
- Feb 13, 2026: Shares held short 10.10M
- Feb 27, 2026: Shares held short 11.84M
- Mar 13, 2026: Shares held short 11.85M
- Mar 31, 2026: Shares held short 11.89M
- Apr 15, 2026: Shares held short 11.49M
- Apr 30, 2026: Shares held short 12.30M
- May 15, 2026: Shares held short 13.57M
- May 29, 2026: Shares held short 11.88M
- Jun 15, 2026: Shares held short 12.92M
- Jun 30, 2026: Shares held short 15.10M
- Jul 15, 2026: Shares held short 13.54M
- Jul 31, 2026: Shares held short 15.68M
- Aug 14, 2026: Shares held short 12.79M
- Aug 31, 2026: Shares held short 13.07M
- Sep 15, 2026: Shares held short 14.20M
- Sep 30, 2026: Shares held short 12.78M
- Oct 15, 2026: Shares held short 11.92M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading71.0% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 71.0% of the shares in the reported trades were short sales, against 69.6% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 71.0%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 69.6%
- Change
- +1.4 pts
- Short sales a dayon average, of 493.4K shares
- 350.3K
- More than atof 3,674 US-listed companies, same days
- 98%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 62.8%
- Oct 15, 2026: Short sales 75.5%
- Oct 16, 2026: Short sales 81.3%
- Oct 19, 2026: Short sales 82.8%
- Oct 20, 2026: Short sales 75.9%
- Oct 21, 2026: Short sales 77.5%
- Oct 22, 2026: Short sales 39.6%
- Oct 23, 2026: Short sales 68.1%
- Oct 26, 2026: Short sales 64.3%
- Oct 27, 2026: Short sales 69.4%
- Oct 28, 2026: Short sales 76.8%
- Oct 29, 2026: Short sales 51%
- Oct 30, 2026: Short sales 76.5%
- Nov 2, 2026: Short sales 78.5%
- Nov 3, 2026: Short sales 77.7%
- Nov 4, 2026: Short sales 55.2%
- Nov 5, 2026: Short sales 69.2%
- Nov 6, 2026: Short sales 73.7%
- Nov 9, 2026: Short sales 75.3%
- Nov 10, 2026: Short sales 83.4%
- Nov 11, 2026: Short sales 62.7%
- Nov 12, 2026: Short sales 57.3%
- Nov 13, 2026: Short sales 67.2%
- Nov 16, 2026: Short sales 70.7%
- Nov 17, 2026: Short sales 72.3%
- Nov 18, 2026: Short sales 61.4%
- Nov 19, 2026: Short sales 82.3%
- Nov 20, 2026: Short sales 89.2%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Michael J. FarrellChairman and CEODirectly493.8K
- Peter C FarrellDirectorDirectly52.2K
- Carol BurtDirectorDirectly19.9K
- Michael J RiderGlobal General CounselDirectly12.9K
- Harjit GillDirectorDirectly12.0K
- Karen DrexlerDirectorDirectly11.7K
- Justin LeongChief Product OfficerDirectly10.3K
- Aaron BloomerChief Financial OfficerDirectly7,977
- Desney TanDirectorDirectly7,111
- John HernandezDirectorDirectly6,227
- Witte Jan DeDirectorDirectly4,881
- Christopher DelOreficeDirectorDirectly2,977
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Michael J. FarrellChairman and CEO | 493.8K | – | Nov 19, 2026 | Form 4 |
| Peter C FarrellDirector | 52.2K | – | Nov 19, 2026 | Form 4 |
| Carol BurtDirector | 19.9K | – | Nov 19, 2026 | Form 4 |
| Michael J RiderGlobal General Counsel | 12.9K | – | Nov 19, 2026 | Form 4 |
| Harjit GillDirector | 12.0K | – | Nov 19, 2026 | Form 4 |
| Karen DrexlerDirector | 11.7K | – | Nov 19, 2026 | Form 4 |
| Justin LeongChief Product Officer | 10.3K | – | Nov 19, 2026 | Form 4 |
| Aaron BloomerChief Financial Officer | 7,977 | – | Nov 11, 2026 | Form 4 |
| Desney TanDirector | 7,111 | – | Nov 19, 2026 | Form 4 |
| John HernandezDirector | 6,227 | – | Nov 19, 2026 | Form 4 |
| Witte Jan DeDirector | 4,881 | – | Nov 19, 2026 | Form 4 |
| Christopher DelOreficeDirector | 2,977 | – | Nov 19, 2026 | Form 4 |
A lower bound: it counts only the 12 officers and directors with a market trade since Nov 22, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
10b5-1 trading plans
Since 2023 every 10-Q and 10-K says which insiders adopted or ended a trading plan (Rule 10b5-1) in the quarter: when, for how many shares, until when. A plan explains the sales that follow months before they show up on Form 4.
- Justin LeongChief Product OfficerWhat happenedAdoptedAug 31, 2026Shares5,000
- Jan De WitteDirectorWhat happenedAdoptedAug 19, 2026Shares429
- Michael RiderChief Legal OfficerWhat happenedAdoptedFeb 20, 2026Shares1,205
- Jan De WitteDirectorWhat happenedAdoptedAug 19, 2025Shares2,055
- Peter C. FarrellChair EmeritusWhat happenedAdoptedAug 12, 2025Shares24.0K
- Michael RiderChief Legal OfficerWhat happenedAdoptedFeb 28, 2025Shares407
- Brett SandercockChief Financial OfficerWhat happenedAdoptedFeb 19, 2025Shares25.5K
- Jan De WitteDirectorWhat happenedAdoptedFeb 3, 2025Shares2,487
- Kaushik GhoshalChief Commercial OfficerWhat happenedAdoptedNov 29, 2024Shares18.9K
- Michael J. FarrellChief Executive OfficerWhat happenedAdoptedOct 31, 2024Shares140.0K
| Person | What happened | Until | Shares | Filing |
|---|---|---|---|---|
| Justin LeongChief Product Officer | AdoptedAug 31, 2026 | May 7, 2027 | 5,000 | 10-Q |
| Jan De WitteDirector | AdoptedAug 19, 2026 | Nov 30, 2026 | 429 | 10-Q |
| Michael RiderChief Legal Officer | AdoptedFeb 20, 2026 | Feb 1, 2027 | 1,205 | 10-Q |
| Jan De WitteDirector | AdoptedAug 19, 2025 | Mar 31, 2026 | 2,055 | 10-Q |
| Peter C. FarrellChair Emeritus | AdoptedAug 12, 2025 | Nov 12, 2026 | 24.0K | 10-Q |
| Michael RiderChief Legal Officer | AdoptedFeb 28, 2025 | Feb 17, 2026 | 407 | 10-Q |
| Brett SandercockChief Financial Officer | AdoptedFeb 19, 2025 | Apr 30, 2026 | 25.5K | 10-Q |
| Jan De WitteDirector | AdoptedFeb 3, 2025 | Nov 11, 2025 | 2,487 | 10-Q |
| Kaushik GhoshalChief Commercial Officer | AdoptedNov 29, 2024 | May 29, 2025 | 18.9K | 10-Q |
| Michael J. FarrellChief Executive Officer | AdoptedOct 31, 2024 | Nov 20, 2026 | 140.0K | 10-Q |
As the company states them in Item 9B of the 10-K and Part II, Item 5 of the 10-Q, with structured data. A plan allows sales on preset dates and prices. It does not say whether all of them will be executed.
Executive pay
From the Pay versus Performance table every company puts in its proxy statement since 2023: what the chief executive was paid, what was actually paid once the shares vest at year-end values, and how the stock did against the peer group the company itself picked.
$16M
Actually paid: -$6.8M
$3.6M
Actually paid: $961.6K
$79
Peers: $82
Adjusted Net Sales
$5.6B
From the proxy statement (DEF 14A) of Oct 1, 2026, as filed with the SEC with structured data. Pay in dollars. The company picks its own peer group and measure. DEF 14A
Share repurchases
How many of its own shares the company bought each quarter, at what average price, for how much, and what remains of the program its board authorized, from the table it puts in every 10-Q and 10-K.
- Jun 30, 202610-KAmount$200M
- Mar 31, 202610-QAmount$175M
- Dec 31, 202510-QAmount$175M
- Sep 30, 202510-QAmount$150M
- Jun 30, 202510-KAmount$100M
- Mar 31, 202510-QAmount$75M
- Dec 31, 202410-QAmount$75M
- Sep 30, 202410-QAmount$50M
| Quarter | Shares | Average price | Amount | Left in the program | Filing |
|---|---|---|---|---|---|
| Jun 30, 202610-K | 972.0K | $205.75 | $200M | 7.92M shares | 10-K |
| Mar 31, 202610-Q | 673.4K | $259.87 | $175M | 8.89M shares | 10-Q |
| Dec 31, 202510-Q | 703.7K | $248.86 | $175M | 9.56M shares | 10-Q |
| Sep 30, 202510-Q | 523.2K | $286.42 | $150M | 10.27M shares | 10-Q |
| Jun 30, 202510-K | 418.7K | $238.81 | $100M | 10.79M shares | 10-K |
| Mar 31, 202510-Q | 314.1K | $238.78 | $75M | 11.21M shares | 10-Q |
| Dec 31, 202410-Q | 306.9K | $244.42 | $75M | 11.52M shares | 10-Q |
| Sep 30, 202410-Q | 222.0K | $225.23 | $50M | 11.83M shares | 10-Q |
From the "Issuer Purchases of Equity Securities" table of the 10-Qs and 10-Ks, read without a model. Only the quarters whose shares times average price agree with the cash the company says it paid for repurchases in its cash-flow statement are shown. The shares include those withheld for officers' taxes. A quarter with an accelerated repurchase shows the table's shares and the cash paid, without an average price.
The shareholders' vote on pay
The advisory say-on-pay vote at each annual meeting, as the company states it in the 8-K it files after the meeting: how many voted for and against the executives' pay. 90% is the norm. Under 70% proxy advisers expect the board to respond the next year.
- 2025Nov 20, 2025For89.9%
- 2024Nov 21, 2024For84.3%
- 2023Nov 20, 2023For81.1%
- 2022Nov 17, 2022For89.9%
- 2021Nov 19, 2021For89.0%
| Year | For | Votes for | Votes against | Abstentions | Broker non-votes | Filing |
|---|---|---|---|---|---|---|
| 2025Nov 20, 2025 | 89.9% | 98.44M | 11.00M | 236.4K | 4.75M | 8-K |
| 2024Nov 21, 2024 | 84.3% | 92.89M | 17.28M | 87.6K | 4.97M | 8-K |
| 2023Nov 20, 2023 | 81.1% | 84.32M | 19.65M | 78.0K | 7.13M | 8-K |
| 2022Nov 17, 2022 | 89.9% | 103M | 11.57M | 254.8K | 4.93M | 8-K |
| 2021Nov 19, 2021 | 89.0% | 99.22M | 12.23M | 220.2K | 5.35M | 8-K |
From the 8-K (item 5.07) the company files after each annual meeting since 2021, read from the filing's text without a model. A company that votes every three years has empty years. The vote is advisory: the board is not bound by it.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IHIiShares U.S. Medical Devices ETFWeight in the fund4.38%
- FTCSFirst Trust Capital Strength ETFWeight in the fund1.72%
- RDVIFT Vest Rising Dividend Achievers Target Income ETFWeight in the fund1.20%
- VFLOVictoryShares Free Cash Flow ETFWeight in the fund1.12%
- RDVYFirst Trust Rising Dividend Achievers ETFWeight in the fund1.11%
- VOTVanguard Mid-Cap Growth Index FundWeight in the fund0.62%
- COWZPacer US Cash Cows 100 ETFWeight in the fund0.56%
- IYHiShares U.S. Healthcare ETFWeight in the fund0.51%
- XLVState Street(R) Health Care Select Sector SPDR(R) ETFWeight in the fund0.49%
- VHTVanguard Health Care Index FundWeight in the fund0.48%
59 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 952
- Q4 2025: Managers 950
- Q1 2026: Managers 948
- Q2 2026: Managers 886
Institutional investors by quarter
The fund managers holding RMD, quarter by quarter, from Q1 2013 to Q2 2025, 50 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 886 managers held 100M shares, worth $19.5B. During the quarter 92 opened a position, 154 closed one, 305 added and 354 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter+1.8%
- Vanguard Capital ManagementIn the quarter
- Vanguard Portfolio ManagementIn the quarter+0.6%
- State StreetIn the quarter+0.6%
- Geode Capital ManagementIn the quarter
- Bank of New York MellonIn the quarter-15%
- First Trust AdvisorsIn the quarter+48%
- InvescoIn the quarter+5.5%
- Morgan StanleyIn the quarter-28%
- Northern TrustIn the quarter-1.7%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 12.32M | +1.8% | $2.4B |
| Vanguard Capital Management | 9.47M | $1.8B | |
| Vanguard Portfolio Management | 7.91M | +0.6% | $1.5B |
| State Street | 6.68M | +0.6% | $1.3B |
| Geode Capital Management | 4.35M | $845M | |
| Bank of New York Mellon | 4.20M | -15% | $818M |
| First Trust Advisors | 2.28M | +48% | $444M |
| Invesco | 2.06M | +5.5% | $402M |
| Morgan Stanley | 1.93M | -28% | $376M |
| Northern Trust | 1.70M | -1.7% | $331M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
The full analysis
What do ResMed's filings show?
Who buys and sells is one part of ResMed's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have RMD's insiders bought or sold?
From Jun 3, 2026 to Nov 20, 2026 ResMed's insiders bought 0 and sold $8.7M of shares on the market. 100% of the sales were under set 10b5-1 plans.
Which well-known managers hold RMD?
6 of the managers we track held the shares on Sep 30, 2026. The largest position was AQR Capital's, worth $209M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.